Phase 1 Study to Assess Safety and Effects of LY4064912 in Healthy Adults and Adults with Overweight or Obesity Using Subcutaneous or Intravenous Administration

What this Trial Is About

Researchers are studying LY4064912 to understand how well it is tolerated and what side effects it may cause in healthy people and those who are overweight or obese. This Phase 1 trial compares different ways of giving the drug, either under the skin subcutaneously or through an intravenous infusion, to see how the body processes it and how it affects participants. The study aims to gather initial safety and drug behavior data in these groups. Participants will receive LY4064912 or a placebo through subcutaneous injections or intravenous infusions in several groups. The trial includes single and multiple doses with escalating amounts to evaluate safety and tolerability. Different parts of the study focus on participants with various body mass index ranges, and some groups receive placebo treatments to compare results. During the study, participants will have regular blood tests to monitor how LY4064912 is processed by the body and to check its effects. Researchers will track serious side effects related to the drug for up to 27 weeks and measure changes in body weight, kidney function, and drug levels in the blood. The total participation time and safety monitoring will ensure thorough evaluation of the drugs impact over time.

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity